# Sotera Health Co: Form 10-Q for the period ended Mar 31, 2025

- Company: [Sotera Health Co](/companies/shc.md) (CIK 1822479)
- Form: 10-Q
- Filed: 2025-05-01
- Accepted by EDGAR: May 1, 2025, 16:05 ET
- Period: 2025-03-31
- Accession: 0001822479-25-000025
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1822479/000182247925000025/shc-20250331.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1822479/000182247925000025/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2025-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2025-01-01 to 2025-03-31 | $254.5m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2025-01-01 to 2025-03-31 | $119.1m | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2025-01-01 to 2025-03-31 | $135.4m | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months, 2025-01-01 to 2025-03-31 | $63.1m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Income tax | 3 months, 2025-01-01 to 2025-03-31 | −$1.6m | us-gaap:IncomeTaxExpenseBenefit |
| Diluted EPS | 3 months, 2025-01-01 to 2025-03-31 | −$0.05 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2025-01-01 to 2025-03-31 | −$0.05 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2025-01-01 to 2025-03-31 | 283,558,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months, 2025-01-01 to 2025-03-31 | $55.5m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months, 2025-01-01 to 2025-03-31 | $19.9m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2025-03-31 | $304.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2025-03-31 | $555.0m | us-gaap:AssetsCurrent |
| Total assets | at 2025-03-31 | $3.10bn | us-gaap:Assets |
| Current liabilities | at 2025-03-31 | $226.0m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2025-03-31 | $2.68bn | us-gaap:Liabilities |
| Long-term debt | at 2025-03-31 | $2.21bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2025-03-31 | $14.8m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | at 2025-03-31 | $414.1m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 35,902 characters.

*You should read the following discussion and analysis in conjunction with our consolidated financial statements and related notes included in Part I, Item 1 of this Quarterly Report on Form 10-Q, as well as the audited consolidated financial statements and notes and Management’s Discussion and Analysis of Financial Condition and Results of Operations contained in our 2024 Form 10-K. This discussion and analysis contains forward-looking statements that are based on management’s current expectations, estimates and projections about our business and operations. Our actual results may differ materially from those currently anticipated and expressed in such forward-looking statements as a result of various factors, including the factors we describe in the section entitled Part II, Item 1A, “Risk Factors” in this Quarterly Report on Form 10-Q, as well as Part I, Item 1A, “Risk Factors” in our 2024 Form 10-K.*

### OVERVIEW

We are a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry. We are driven by our mission: Safeguarding Global Health®. We provide end-to-end sterilization as well as microbiological and analytical lab testing and advisory services to help ensure that medical, pharmaceutical and food products are safe for healthcare practitioners, patients and consumers in the United States and around the world. Our services are an essential aspect of our customers’ manufacturing processes and supply chains, helping to ensure sterilized medical products reach healthcare practitioners and patients. Most of these services are necessary for our customers to satisfy applicable government requirements.

We serve our customers throughout their product lifecycles, from product design to manufacturing and delivery, helping to ensure the sterility, effectiveness and safety of their products for the end user. We operate across two core businesses: sterilization services and lab services. Each of our businesses has a longstanding record and is a leader in its respective market, supported and connected by our core capabilities including deep end market, regulatory, technical and logistics expertise. The combination of Sterigenics, our terminal sterilization business, and Nordion, our Co-60 supply business, makes us the only vertically integrated global gamma sterilization provider in the sterilization industry. This provides us with additional insights and allows us to better serve our customers. For financial reporting purposes, our sterilization services business is comprised of two reportable segments, Sterigenics and Nordion, and our lab services business constitutes a third reportable segment, Nelson Labs.

For the three months ended March 31, 2025, we recorded net revenues of $254.5 million, net loss of $13.3 million, Adjusted Net Income of $39.0 million and Adjusted EBITDA of $121.8 million. Adjusted Net Income and Adjusted EBITDA are financial measures not based on any standardized methodology prescribed by U.S. Generally Accepted Accounting Principles (“GAAP”). For the definition of Adjusted Net Income and Adjusted EBITDA and the reconciliation of these non-GAAP measures from net income (loss), please see “Non-GAAP Financial Measures.”

### CONSOLIDATED RESULTS OF OPERATIONS

### Three Months Ended March 31, 2025, as compared to Three Months Ended March 31, 2024

The following table sets forth the components of our results of operations for the three months ended March 31, 2025 and 2024:

| (thousands of U.S. dollars) | 2025 | 2024 | $ Change | % Change |
| --- | ---: | ---: | ---: | ---: |
| **Total net revenues** | **$254,523** | $248,176 | $6,347 | 2.6% |
| **Total cost of revenues** | **119,091** | 121,061 | (1,970) | (1.6)% |
| **Net (loss) income** | **(13,260)** | 6,323 | (19,583) | (309.7)% |
| **Adjusted Net Income(a)** | **39,044** | 35,630 | 3,414 | 9.6% |
| **Adjusted EBITDA(a)** | **121,839** | 111,944 | 9,895 | 8.8% |

(a) Adjusted Net Income and Adjusted EBITDA are non-GAAP financial measures. For more information regarding our calculation of Adjusted Net Income and Adjusted EBITDA, including information about their limitations as tools for analysis and a reconciliation of net (loss) income, the most directly comparable financial measure calculated and presented in accordance with GAAP, to Adjusted Net Income and Adjusted EBITDA, please see the reconciliation included below in “Non-GAAP Financial Measures.”

### Total Net Revenues

The following table compares our revenues by type for the three months ended March 31, 2025 to the three months ended March 31, 2024:

| (thousands of U.S. dollars) Net revenues for the three months ended March 31, | 2025 | 2024 | $ Change | % Change |
| --- | ---: | ---: | ---: | ---: |
| Service | **$223,940** | $226,481 | $(2,541) | (1.1)% |
| Product | **30,583** | 21,695 | 8,888 | 41.0% |
| **Total net revenues** | **$254,523** | $248,176 | $6,347 | 2.6% |

Net revenues were $254.5 million in the three months ended March 31, 2025, an increase of $6.3 million, or 2.6%, as compared with the three months ended March 31, 2024. Excluding the impact of foreign currency exchange rates, net revenues in the three months ended March 31, 2025 increased approximately 4.4% compared with the three months ended March 31, 2024.

#### Service revenues

Service revenues decreased $2.5 million, or 1.1%, to $223.9 million for the three months ended March 31, 2025, as compared to $226.5 million for the three months ended March 31, 2024. Favorable pricing, combined with growth in core lab testing services was offset by a decline in expert advisory service revenue and unfavorable changes in foreign currency exchange rates across all segments.

#### Product revenues

Product revenues increased $8.9 million, or 41.0%, to $30.6 million for the three months ended March 31, 2025, as compared to $21.7 million for the three months ended March 31, 2024. Favorable volume and mix at Nordion, which was primarily attributable to Co-60 harvest schedule timing, was the main driver of the increase in product revenues in the three months ended March 31, 2025 compared to the same period in the prior year, partially offset by changes in foreign currency exchange rates.

### Total Cost of Revenues

The following table compares our cost of revenues by type for the three months ended March 31, 2025 to the three months ended March 31, 2024:

| (thousands of U.S. dollars) Cost of revenues for the three months ended March 31, | 2025 | 2024 | $ Change | % Change |
| --- | ---: | ---: | ---: | ---: |
| Service | **$107,629** | $110,852 | $(3,223) | (2.9)% |
| Product | **11,462** | 10,209 | 1,253 | 12.3% |
| **Total cost of revenues** | **$119,091** | $121,061 | $(1,970) | (1.6)% |

Total cost of revenues accounted for approximately 46.8% and 48.8% of our consolidated net revenues for the three months ended March 31, 2025 and 2024, respectively.

#### Cost of service revenues

Cost of service revenues decreased $3.2 million, or 2.9%, for the three months ended March 31, 2025, as compared to the three months ended March 31, 2024. Lower employee compensation costs, due mainly to lab optimization activities in the Nelson Labs segment, was the main driver of the decrease. Changes in foreign currency exchange rates had a $1.9 million favorable impact to cost of service revenues in the three months ended March 31, 2025 compared to the same period in the prior year.

#### Cost of product revenues

Cost of product revenues increased $1.3 million, or 12.3%, for the three months ended March 31, 2025, as compared to the three months ended March 31, 2024. The increase was primarily a result of higher volumes of Co-60 shipments, which resulted in increases in direct material and material transportation costs of $2.2 million. This was partially offset by a $1.0 million decrease in amortization of intangible assets that were fully amortized as of December 31, 2024. Changes in foreign currency exchange rates had a $0.5 million favorable impact to cost of product revenues in the three months ended March 31, 2025 compared to the same period in the prior year.

### SG&A Expenses

SG&A expenses increased $4.9 million, or 8.3%, for the three months ended March 31, 2025, as compared to the three months ended March 31, 2024. A $6.3 million increase in litigation and other professional services expense associated with EO sterilization facilities was the main driver of the increase in SG&A expenses, partially offset by a $1.4 million decline in share-based compensation expense.

### Amortization of intangible assets

Amortization of intangible assets decreased $0.4 million, or 2.6% for the three months ended March 31, 2025, as compared to the three months ended March 31, 2024 due mainly to changes in foreign currency exchange rates.

### Illinois EO litigation settlement

On April 3, 2025, the Company agreed to resolve 97 pending and threatened EO claims in the State of Illinois. Pursuant to the terms of the Term Sheet, which is subject to the satisfaction of several conditions, the Company agreed to pay $30.9 million to settle the claims.

### Interest Expense, Net

Interest expense, net decreased $0.9 million, or 2.1%, for the three months ended March 31, 2025, as compared to the three months ended March 31, 2024, primarily due to a decline in the variable interest rate on our Term Loan. The weighted average interest rate on our outstanding debt was 7.49% and 8.39% at March 31, 2025 and 2024, respectively.

### Foreign Exchange Loss (Gain)

Foreign exchange loss was $0.3 million for the three months ended March 31, 2025 compared to a gain of $0.6 million for the three months ended March 31, 2024. The change in foreign exchange loss (gain) mainly relates to short-term gains and losses on transactions denominated in currencies other than the functional currency of our operating entities. As described in Note 15, “Financial Instruments and Financial Risk,” we enter into monthly U.S. dollar-denominated foreign currency forward contracts to manage foreign currency exchange rate risk related to our international subsidiaries.

### Other (Income) Expense, Net

Other income, net increased $1.2 million for the three months ended March 31, 2025 as compared to the three months ended March 31, 2024. The variance was primarily a result of $0.7 million of refinancing costs recognized in the three months ended March 31, 2024 (associated with Amendment No. 3 to the Revolving Credit Facility) that was not incurred in the three months ended March 31, 2025.

### (Benefit) Provision for Income Taxes

The Company recognized a $1.6 million benefit for income taxes in the three months ended March 31, 2025, as compared to a $4.7 million income tax provision for the three months ended March 31, 2024. The change was primarily attributable to a pre-tax loss in the three months ended March 31, 2025 compared to pre-tax income in the three months ended March 31, 2024, partially offset by an increase in current year permanent tax differences.

Benefit for income taxes for the three months ended March 31, 2025 differed from the statutory rate primarily due to current year permanent differences, partially offset by the valuation allowance attributable to the limitation on the deductibility of interest expense and the impact of the foreign rate differential. Provision for income taxes for the three months ended March 31, 2024 differed from the statutory rate primarily due to an increase in the valuation allowance against our excess interest expense carryforward balance and the impact of the foreign rate differential, partially offset by a benefit for state income taxes.

### Net Loss/Income, Adjusted Net Income and Adjusted EBITDA

Net loss for the three months ended March 31, 2025 was $13.3 million, as compared to net income of $6.3 million for the three months ended March 31, 2024. Adjusted Net Income was $39.0 million for the three months ended March 31, 2025, as compared to $35.6 million for the three months ended March 31, 2024, due to the factors described above. Adjusted EBITDA was $121.8 million for the three months ended March 31, 2025, as compared to $111.9 million for the three months ended March 31, 2024, due to the factors described above. Please see “Non-GAAP Financial Measures” below for a reconciliation of

Adjusted Net Income and Adjusted EBITDA to their most directly comparable financial measure calculated and presented in accordance with GAAP.

### NON-GAAP FINANCIAL MEASURES

To supplement our consolidated financial statements presented in accordance with GAAP, we consider Adjusted Net Income and Adjusted EBITDA, financial measures that are not based on any standardized methodology prescribed by GAAP.

We define Adjusted Net Income as net income before amortization and certain other adjustments that we do not consider in our evaluation of our ongoing operating performance from period to period as discussed further below. We define Adjusted EBITDA as Adjusted Net Income before interest expense, depreciation (including depreciation of Co-60 used in our operations) and income tax provision applicable to Adjusted Net Income.

We use Adjusted Net Income and Adjusted EBITDA, non-GAAP financial measures, as the principal measures of our operating performance. Management believes Adjusted Net Income and Adjusted EBITDA are useful because they allow management to more effectively evaluate our operating performance and compare the results of our operations from period to period without the impact of certain non-cash items and non-routine items that we do not expect to continue at the same level in the future and other items that are not core to our operations. We believe that these measures are useful to our investors because they provide a more complete understanding of the factors and trends affecting our business than could be obtained absent this disclosure. In addition, we believe Adjusted Net Income and Adjusted EBITDA will assist investors in making comparisons to our historical operating results and analyzing the underlying performance of our operations for the periods presented. Our management also uses Adjusted Net Income and Adjusted EBITDA in its financial analysis and operational decision-making, and Adjusted EBITDA serves as the basis for the metric we utilize to determine attainment of our primary annual incentive program. Adjusted Net Income and Adjusted EBITDA may be calculated differently from, and therefore may not be comparable to, a similarly titled measure used by other companies.

Adjusted Net Income and Adjusted EBITDA should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. There are a number of limitations related to the use of Adjusted Net Income and Adjusted EBITDA rather than net income (loss), the nearest GAAP equivalent. For example, Adjusted Net Income and Adjusted EBITDA primarily exclude:

- certain recurring non-cash charges such as depreciation of fixed assets, although these assets may have to be replaced in the future, as well as amortization of acquired intangible assets and asset retirement obligations (“ARO”);
- costs of acquiring and integrating businesses, which will continue to be a part of our growth strategy;
- non-cash gains or losses from fluctuations in foreign currency exchange rates, and the mark-to-fair value of derivatives not designated as hedging instruments, which includes the embedded derivatives relating to certain customer and supply contracts at Nordion;
- impairment charges on long-lived assets, intangible assets and investments accounted for under the equity method;
- loss on refinancing of debt incurred in connection with refinancing or early extinguishment of long-term debt;
- expenses incurred in connection with the secondary offering of our common stock and other shareholder activities;
- expenses and charges related to the litigation, settlement agreements, and other activities associated with our EO sterilization facilities, including those related to Willowbrook, Illinois, Atlanta, Georgia, Santa Teresa, New Mexico and Vernon, California;
- in the case of Adjusted EBITDA, interest expense or the cash requirements necessary to service interest or principal payments on our indebtedness; and
- share-based compensation expense, which has been, and will continue to be for the foreseeable future, a significant recurring expense and an important part of our compensation strategy.

In evaluating Adjusted Net Income and Adjusted EBITDA, you should be aware that in the future, we will incur expenses similar to the adjustments in this presentation. Our presentations of Adjusted Net Income and Adjusted EBITDA should not be construed as suggesting that our future results will be unaffected by these expenses or any unusual or non-recurring items. When evaluating our performance, you should consider Adjusted Net Income and Adjusted EBITDA alongside other financial performance measures, including our net income and other GAAP measures.

The following table presents a reconciliation of net income, the most directly comparable financial measure calculated and presented in accordance with GAAP to Adjusted Net Income and Adjusted EBITDA, for each of the periods indicated:

| (thousands of U.S. dollars) | Three Months Ended March 31, 2025 | 2024 |
| --- | ---: | ---: |
| **Net (loss) income** | **$(13,260)** | $6,323 |
| Amortization of intangible assets | **18,674** | 20,124 |
| Share-based compensation(a) | **7,269** | 8,657 |
| Loss on foreign currency and derivatives not designated as hedging instruments, net(b) | **1,891** | 1,230 |
| Business optimization expenses(c) | **2,047** | 54 |
| Refinancing and secondary offering costs(d) | **—** | 1,807 |
| Professional services relating to EO sterilization facilities(e) | **12,328** | 6,339 |
| Illinois EO litigation settlement(f) | **30,943** | — |
| Accretion of asset retirement obligations(g) | **574** | 642 |
| Income tax benefit associated with pre-tax adjustments(h) | **(21,422)** | (9,546) |
| **Adjusted Net Income** | **39,044** | 35,630 |
| Interest expense, net | **40,876** | 41,771 |
| Depreciation(i) | **22,060** | 20,306 |
| Income tax provision applicable to Adjusted Net Income(j) | **19,859** | 14,237 |
| **Adjusted EBITDA(k)** | **$121,839** | $111,944 |

(a) Represents share-based compensation expense to employees and Non-Employee Directors.

(b) Represents the effects of (i) fluctuations in foreign currency exchange rates and (ii) non-cash mark-to-fair value of embedded derivatives relating to certain customer and supply contracts at Nordion.

(c) Represents certain costs related to divestitures, acquisitions and the integration of recent acquisitions, as well as professional fees and other costs associated with business optimization, cost saving and other process enhancement projects.

(d) The three months ended March 31, 2024 includes $1.1 million of expenses incurred in connection with the secondary offering of our common stock that closed on March 4, 2024 and write-off of unamortized debt issuance costs in connection with Amendment No. 3 to the Revolving Credit Facility.

(e) Represents litigation and other professional fees associated with our EO sterilization facilities.

(f) Represents the cost to settle 97 pending and threatened EO claims against Sterigenics in Illinois pursuant to the Term Sheet entered into on April 3, 2025. See Note 14, “Commitments and Contingencies.”

(g) Represents non-cash accretion of ARO related to Co-60 gamma and EO processing facilities, which are based on estimated site remediation costs for any future decommissioning of these facilities and are accreted over the life of the asset.

(h) Represents the income tax impact of adjustments calculated based on the tax rate applicable to each item. We eliminate the effect of tax rate changes as applied to tax assets and liabilities and unusual items from our presentation of adjusted net income.

(i) Includes depreciation of Co-60 held at gamma irradiation sites. The three months ended March 31, 2025 excludes accelerated depreciation associated with business optimization activities.

(j) Represents the difference between the income tax provision as determined under U.S. GAAP and the income tax provision or benefit associated with pre-tax adjustments described in footnote (h).

(k) $24.2 million and $23.8 million of the adjustments for the three months ended March 31, 2025 and 2024, respectively, are included in cost of revenues, primarily consisting of amortization of intangible assets, depreciation, and accretion of asset retirement obligations.

### SEGMENT RESULTS OF OPERATIONS

We have three reportable segments: Sterigenics, Nordion and Nelson Labs. Our chief operating decision maker evaluates performance and allocates resources within our business based on segment income, which excludes certain items which are included in income (loss) before tax as determined in our Consolidated Statements of Operations and Comprehensive Income (Loss). The accounting policies for our reportable segments are the same as those for the consolidated Company.

### Our Segments

### Sterigenics

Sterigenics provides outsourced terminal sterilization and irradiation services for the medical device, pharmaceutical, food safety and advanced applications markets using three major technologies: gamma irradiation, EO processing and E-beam irradiation.

### Nordion

Our Nordion business is a leading global provider of Co-60 used in the sterilization and irradiation processes for the medical device, pharmaceutical, food safety, and high-performance materials industries, as well as in the treatment of cancer. In addition, Nordion is a leading global provider of gamma irradiation systems.

As a result of the time required to meet regulatory and logistics requirements for delivery of radioactive products, combined with accommodations that we make to our customers to minimize disruptions to their operations during the installation of Co-60, Nordion sales patterns can often vary significantly from one quarter to the next. In most cases, however, timing-related impacts on our sales performance tend to be resolved within several quarters, resulting in more consistent performance over longer periods of time. In addition, sales of gamma irradiation systems occur infrequently and tend to be for larger amounts. Nordion’s results of operations are also impacted by Co-60 harvest schedules.

### Nelson Labs

Our Nelson Labs business provides outsourced microbiological and analytical chemistry testing and advisory services for the medical device and pharmaceutical industries.

For more information regarding our reportable segments please refer to Note 16, “Segment Information” to our consolidated financial statements.

### Segment Results for the Three Months Ended March 31, 2025 and 2024

The following tables compare segment net revenue and segment income for the three months ended March 31, 2025 to the three months ended March 31, 2024:

| (thousands of U.S. dollars) Net Revenues | Three Months Ended March 31, 2025 | 2024 | $ Change | % Change |
| --- | ---: | ---: | ---: | ---: |
| Sterigenics | **$169,684** | $166,497 | $3,187 | 1.9% |
| Nordion | **32,557** | 24,007 | 8,550 | 35.6% |
| Nelson Labs | **52,282** | 57,672 | (5,390) | (9.3)% |
| **Segment Income** |  |  |  |  |
| Sterigenics | **$88,004** | $85,818 | $2,186 | 2.5% |
| Nordion | **17,422** | 10,785 | 6,637 | 61.5% |
| Nelson Labs | **16,413** | 15,341 | 1,072 | 7.0% |
| **Segment Income margin** |  |  |  |  |
| Sterigenics | **51.9%** | 51.5% |  |  |
| Nordion | **53.5%** | 44.9% |  |  |
| Nelson Labs | **31.4%** | 26.6% |  |  |

#### Net Revenues by Segment

Sterigenics net revenues were $169.7 million for the three months ended March 31, 2025, an increase of $3.2 million, or 1.9%, as compared to the three months ended March 31, 2024. The increase reflects a benefit from pricing of 4.1%, partially offset by an unfavorable impact from changes in foreign currency exchange rates of 1.9%.

Nordion net revenues were $32.6 million for the three months ended March 31, 2025, an increase of $8.6 million, or 35.6%, as compared to the three months ended March 31, 2024. Revenue growth was driven mainly by volume and mix, which was largely attributable to a more favorable Co-60 harvest schedule timing for the three months ended March 31, 2025 compared to the three months ended March 31, 2024, partially offset by an unfavorable impact from changes in foreign currency exchange rates of 5.0%.

Nelson Labs net revenues were $52.3 million for the three months ended March 31, 2025, a decrease of $5.4 million, or 9.3%, as compared to the three months ended March 31, 2024. Favorable pricing and improvement in core lab testing services was offset by a decline in expert advisory service revenue and changes in foreign currency exchange rates.

#### Segment Income

Sterigenics segment income was $88.0 million for the three months ended March 31, 2025, an increase of $2.2 million, or 2.5%, as compared to the three months ended March 31, 2024. Segment income and segment income margin increased primarily due to the benefit of pricing, partially offset by inflation and changes in foreign currency exchange rates.

Nordion segment income was $17.4 million for the three months ended March 31, 2025, an increase of $6.6 million, or 61.5%, as compared to the three months ended March 31, 2024. The increase in segment income and segment income margin was primarily driven by higher volume and mix, stemming from favorable Co-60 harvest schedule timing, as referenced above.

Nelson Labs segment income was $16.4 million for the three months ended March 31, 2025, an increase of $1.1 million, or 7.0%, as compared to the three months ended March 31, 2024. The increase in segment income and segment income margin was attributable to favorable pricing and volume/mix improvements in core lab testing services coupled with lab optimization, partially offset by lower volume/mix in expert advisory services.

### LIQUIDITY AND CAPITAL RESOURCES

### Sources of Cash

The primary sources of liquidity for our business are cash flows from operations and borrowings under our credit facilities. As of March 31, 2025, we had $304.4 million of cash and cash equivalents. This is an increase of $27.1 million from the balance at December 31, 2024. The increase in cash and cash equivalents was attributable to $55.5 million of cash provided by operating activities, partially offset by $19.9 million of cash paid for purchases of property, plant and equipment and $8.1 million of cash used in financing activities. Our foreign subsidiaries held cash of approximately $291.6 million at March 31, 2025 and $259.8 million at December 31, 2024. No material restrictions exist to accessing cash held by our foreign subsidiaries notwithstanding any potential tax consequences.

### Uses of Cash

We expect that cash on hand, operating cash flows and amounts available under our credit facilities will provide sufficient working capital to operate our business, meet foreseeable liquidity requirements (inclusive of debt service on our long-term debt), make expected capital expenditures including investments in fixed assets to build and/or expand existing facilities, and meet litigation costs that we expect to continue to incur for at least the next twelve months and the foreseeable future thereafter. Our primary long-term liquidity requirements beyond the next 12 months will be to service our debt, make capital expenditures, and fund suitable business acquisitions. As of March 31, 2025, there were no outstanding borrowings on the Revolving Credit Facility. We expect any excess cash provided by operations will be allocated to fund capital expenditures, potential acquisitions, or for other general corporate purposes. Our ability to meet future working capital, capital expenditures and debt service requirements will depend on our future financial performance, which will be affected by a range of macroeconomic, competitive and business factors, including interest rate changes and changes in our industry, many of which are outside of our control. As of March 31, 2025, our interest rate derivatives limit our cash flow exposure of our variable rate borrowings under the Term Loans. Refer to Note 15, “Financial Instruments and Financial Risk,” “Derivative Instruments” for additional information about changes in interest rate risk.

### Capital Expenditures

Our capital expenditure program is a component of our long-term strategy. This program includes, among other things, investments in new and existing facilities, business expansion projects, Co-60 used by Sterigenics at its gamma irradiation facilities, cobalt development projects and information technology enhancements. During the three months ended March 31, 2025, our capital expenditures amounted to $19.9 million, compared to $34.9 million for the three months ended March 31, 2024.

### Cash Flow Information

### Three Months Ended March 31, 2025 compared to the Three Months Ended March 31, 2024

| (thousands of U.S. dollars) Net Cash Provided by (Used in): | 2025 | 2024 |
| --- | ---: | ---: |
| Operating activities | **$55,521** | $9,699 |
| Investing activities | **(19,881)** | (34,853) |
| Financing activities | **(8,087)** | (11,941) |
| Effect of foreign currency exchange rate changes on cash and cash equivalents | **(337)** | (1,739) |
| **Net increase (decrease) in cash and cash equivalents, including restricted cash, during the period** | **$27,216** | $(38,834) |

#### Operating activities

Cash flows provided by operating activities increased $45.8 million to net cash provided of $55.5 million for the three months ended March 31, 2025 compared to $9.7 million for the three months ended March 31, 2024. The increase in cash flows from operating activities in the three months ended March 31, 2025 compared to the three months ended March 31, 2024 was driven primarily by the $35.0 million payment of the Georgia EO litigation settlement in the three months ended March 31, 2024.

#### Investing activities

Cash used in investing activities decreased $15.0 million to net cash used of $19.9 million for the three months ended March 31, 2025 compared to $34.9 million for the three months ended March 31, 2024. The variance was driven by a decrease in capital expenditures of $15.0 million in the three months ended March 31, 2025 compared to the three months ended March 31, 2024.

#### Financing activities

Cash used in financing activities decreased by $3.9 million to $8.1 million for the three months ended March 31, 2025 compared to $11.9 million for the three months ended March 31, 2024. The difference was due mainly to a $6.7 million payment to settle a finance lease in 2024, partially offset by an increase of $2.5 million in principal payments on long-term borrowings.

### Debt Facilities

On December 13, 2019, SHH, our wholly owned subsidiary, entered into senior secured first lien credit facilities (the “Senior Secured Credit Facilities”), consisting of both a prepayable senior secured first lien term loan (the “Term Loan”) and a senior secured first lien revolving credit facility (the “Revolving Credit Facility”) pursuant to a first lien credit agreement (as amended through Amendment No. 5 (as defined below), the “Credit Agreement”). Amendment No. 5 increased the total borrowing capacity under the Revolving Credit Facility to $600.0 million. The Senior Secured Credit Facilities also provide SHH the right at any time and under certain conditions to request incremental term loans or incremental revolving credit commitments based on a formula defined in the Senior Secured Credit Facilities.

On April 30, 2025, the Company and SHH entered into Amendment No. 5 (“Amendment No. 5”) to the Revolving Credit Facility. Among other changes, Amendment No. 5 provides (i) for an increase in the commitments under the existing Revolving Credit Facility in an aggregate principal amount of $176.2 million, (ii) that certain lenders providing revolving credit commitments shall also provide additional commitments for the issuance of letters of credit under the Revolving Credit Facility in an aggregate principal amount of $186.3 million and (iii) for the extension of the maturity date of the Revolving Credit Facility to April 30, 2030. Amendment No. 5 does not give effect to any other material changes to the terms and conditions of the Credit Agreement, including with respect to the representations and warranties, events of default and the affirmative or negative covenants.

The Company and SHH had previously entered into Amendments No. 4 and Amendment No. 3 on May 30, 2024 and March 1, 2024, respectively. See Note 8, “Long-Term Debt,” to the Financial Statements for a description of these amendments.

On May 30, 2024, SHH, the Company, certain subsidiaries of the Company, and Wilmington Trust, National Association, as trustee, paying agent, registrar, transfer agent and notes collateral agent, entered into an Indenture (the “Indenture”) governing SHH’s $750.0 million aggregate principal amount of 7.375% senior secured notes due 2031 (the “Secured Notes”) issued in May 2024.

The Senior Secured Credit Facilities and the Indenture contain certain covenants and events of default. Additionally, all of SHH’s obligations under the Senior Secured Credit Facilities and the Indenture are unconditionally guaranteed by the Company and certain domestic restricted subsidiaries. For additional information about our Senior Secured Credit Facilities, the Indenture and the Secured Notes, including the covenants and events of default, refer to Note 8, “Long-Term Debt,” to our Financial Statements.

Outstanding letters of credit are collateralized by encumbrances against the Revolving Credit Facility and the collateral pledged thereunder, or by cash placed on deposit with the issuing bank. As of April 30, 2025, the Company had $13.7 million of letters of credit issued against the Revolving Credit Facility, resulting in total availability under the Revolving Credit Facility of $586.3 million.

#### Term Loan Interest Rate Risk Management

The Company utilizes interest rate derivatives to reduce the variability of cash flows in the interest payments associated with our variable rate debt due to changes in SOFR. For additional information on the derivative instruments described above, refer to Note 15, “Financial Instruments and Financial Risk,” “*Derivative Instruments.”*

### CRITICAL ACCOUNTING POLICIES AND ESTIMATES

The preparation of consolidated financial statements and related disclosures in conformity with GAAP requires management to make judgments, estimates and assumptions at a specific point in time and in certain circumstances that affect amounts reported in the accompanying consolidated financial statements. In preparing these consolidated financial statements, management has made its best estimates and judgments of certain amounts, giving due consideration to materiality. The application of accounting policies involves the exercise of judgment and use of assumptions as to future uncertainties and, as a result, actual results could differ from these estimates.

A comprehensive discussion of the Company’s critical accounting policies and management estimates made in connection with the preparation of the financial statements is included in Item 7 of our 2024 Form 10-K. There have been no significant changes in critical accounting policies, management estimates or accounting policies since the year ended December 31, 2024.

### NEW ACCOUNTING PRONOUNCEMENTS

For a description of recent accounting pronouncements applicable to our business, see Note 2, “Recent Accounting Standards,” to our consolidated financial statements.

## Market risk

As filed, 227 characters.

Market risks are described within “Quantitative and Qualitative Disclosures About Market Risk” in Part II, Item 7A of our 2024 Form 10-K. These market risks have not materially changed for the three months ended March 31, 2025.

## Controls and procedures

As filed, 1,317 characters.

### Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the Company’s “disclosure controls and procedures,” (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based upon their evaluation, the Chief Executive Officer and Chief Financial Officer concluded that, as of the end of the period covered by this Quarterly Report on Form 10-Q, our disclosure controls and procedures are effective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission (the “SEC”), and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

### Changes in Internal Control

During the three months ended March 31, 2025, there were no changes in our internal control over financial reporting that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Filed May 1, 2025.
Source: SEC EDGAR, the filing index for accession 0001822479-25-000025. Last ingested by Listed: Nov 3, 2026, 18:50 ET. No prices; not investment advice.
